Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
Candel Therapeutics announced that extended Phase 3 data from their lead immunotherapy candidate, Aglatimagene Besadenovec, will be presented at the 2026 ASTRO Annual Meeting. The company specializes in multimodal biological immunotherapies targeting difficult-to-treat solid tumors, with ongoing clinical trials and several FDA designations supporti…